Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy
dc.contributor.author | Patel, KP | en_US |
dc.contributor.author | Lansky, AJ | en_US |
dc.contributor.author | Kereiakes, DJ | en_US |
dc.contributor.author | Windecker, S | en_US |
dc.contributor.author | Cristea, E | en_US |
dc.contributor.author | Pietras, C | en_US |
dc.contributor.author | Dressler, O | en_US |
dc.contributor.author | Issever, MO | en_US |
dc.contributor.author | Curtis, M | en_US |
dc.contributor.author | Bertolet, B | en_US |
dc.contributor.author | Zidar, JP | en_US |
dc.contributor.author | Smits, PC | en_US |
dc.contributor.author | Jiménez Díaz, VA | en_US |
dc.contributor.author | McLaurin, B | en_US |
dc.contributor.author | Brogno, DA | en_US |
dc.contributor.author | Janssens, L | en_US |
dc.contributor.author | Vrolix, MC | en_US |
dc.contributor.author | Gómez-Blázquez, I | en_US |
dc.contributor.author | Sahul, ZH | en_US |
dc.contributor.author | Kabour, A | en_US |
dc.contributor.author | Salido, L | en_US |
dc.contributor.author | Cleman, M | en_US |
dc.contributor.author | Saito, S | en_US |
dc.contributor.author | Leon, MB | en_US |
dc.contributor.author | Baumbach, A | en_US |
dc.date.accessioned | 2022-11-29T14:33:53Z | |
dc.date.issued | 2022-01-01 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/82840 | |
dc.description.abstract | Background: The Supreme healing-targeted drug-eluting stent (DES) is designed to promote endothelial healing to reduce stent-related adverse events. This may be particularly relevant among complex lesions that have a higher rate of adverse events. We sought to compare 1-year outcomes of percutaneous coronary intervention in complex lesions between the Supreme DES and contemporary durable-polymer, everolimus-eluting stents (DP-EES). Methods: PIONEER III was a multicenter, prospective, single-blind clinical trial, randomizing 1629 patients with either an acute or chronic coronary syndrome in a 2:1 ratio to the Supreme DES or DP-EES. Complex lesions (American College of Cardiology/American Heart Association type B2/C) were found in 1137 patients. Outcomes were also compared for specific parameters of lesion complexity: severe calcification, long length (>20 mm), and severe tortuosity. The primary end point was target lesion failure at 1 year. Results: At 1 year, there was no difference in target lesion failure between the Supreme DES and DP-EES: (5.7% vs 5.6%; hazard ratio 1.00, 95% confidence interval 0.59-1.68, P =.99). Similarly, there were no differences in the secondary end points of lesion success (99.7% vs 99.4%, P =.41), device success (97.0% vs 98.5%, P =.14), target vessel failure (6.5% vs 7.4%, P =.50), major adverse cardiac events (7.8% vs 8.5%, P =.64), or stent thrombosis (0.7% vs 1.1%, P =.48). A trend was observed toward a higher rate of target lesion revascularization with the Supreme DES (2.5% vs 0.9%, P =.06). Conclusions: This study suggests that the Supreme DES is as effective and safe at 1 year compared with the standard DP-EES across a broad spectrum of lesion complexity. | en_US |
dc.relation.ispartof | Journal of the Society for Cardiovascular Angiography and Interventions | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1016/j.jscai.2021.100004 | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 1 | en_US |